Carisma Therapeutics (CARM) Projected to Post Earnings on Monday

Posted by ABMN Staff on Mar 29th, 2026

Carisma Therapeutics (NASDAQ:CARM – Get Free Report) is anticipated to post its Q4 2025 results after the market closes on Monday, March 30th. Analysts expect Carisma Therapeutics to post earnings of ($0.1474) per share and revenue of $4.2290 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:00 PM ET.

Carisma Therapeutics Stock Down 0.3%

Shares of CARM opened at $0.03 on Friday. The firm has a market cap of $1.38 million, a PE ratio of 0.05 and a beta of 1.86. The company’s fifty day moving average is $0.04 and its two-hundred day moving average is $0.08. Carisma Therapeutics has a fifty-two week low of $0.03 and a fifty-two week high of $1.27.

Institutional Investors Weigh In On Carisma Therapeutics

An institutional investor recently bought a new position in Carisma Therapeutics stock. Jane Street Group LLC acquired a new position in shares of Carisma Therapeutics Inc. (NASDAQ:CARM – Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 150,810 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned 0.36% of Carisma Therapeutics at the end of the most recent quarter. Institutional investors own 44.27% of the company’s stock.

Carisma Therapeutics Company Profile

(Get Free Report)

Carisma Therapeutics, Inc is a clinical-stage biotechnology company headquartered in the United States that focuses on harnessing the innate immune system to treat cancer and inflammatory diseases. Through its proprietary CARMA (Chimeric Antigen Receptor Macrophage) platform, Carisma engineers macrophages and other myeloid cells to seek out, engulf and destroy diseased cells while reprogramming the surrounding microenvironment. This approach aims to address key limitations of existing T-cell therapies by leveraging the unique trafficking and immunomodulatory properties of innate immune cells.

The company’s lead oncology candidate, CT-0508, employs a HER2-targeted CAR expressed on macrophages to infiltrate and remodel HER2-positive solid tumors.